Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.68 |
| ▸ | INSR | P06213 | 3/20 | 0.54 |
| ▸ | IGF1R | P08069 | 3/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23154002 | 0.90 | EGFR (0.62) | EGFR | |
| SCHEMBL23154062 | 0.89 | EGFR (0.72) | EGFRINSRIGF1RALK | |
| SCHEMBL24756620 | 0.89 | EGFR (0.72) | EGFRINSRIGF1RALK | |
| SCHEMBL23154204 | 0.89 | EGFR (0.71) | EGFRINSRIGF1RALK | |
| SCHEMBL23153743 | 0.89 | EGFR (0.75) | EGFRINSRIGF1RALK | |
| SCHEMBL23153843 | 0.89 | EGFR (0.71) | EGFRINSRIGF1RALK | |
| SCHEMBL23154232 | 0.88 | EGFR (0.69) | EGFRINSRIGF1RALK | |
| SCHEMBL23153808 | 0.88 | EGFR (0.70) | EGFRINSRIGF1RALK | |
| SCHEMBL23154284 | 0.88 | EGFR (0.70) | EGFRINSRIGF1RALK | |
| SCHEMBL24179083 | 0.88 | EGFR (0.77) | EGFRINSRIGF1RALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114502564-A | EGFR inhibitor, composition and preparation method thereof | 贝达药业股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| CN-114502564-A | EGFR inhibitor, composition and preparation method thereof | 贝达药业股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021057882-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | 贝达药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | EGFR, ERBB2, ERBB3 | EGFR 1/4885INSR 149/4885IGF1R 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.